• Aucun résultat trouvé

The Free Fatty Acid Receptor GPR40 Protects from Bone Loss through Inhibition of Osteoclast Differentiation

N/A
N/A
Protected

Academic year: 2021

Partager "The Free Fatty Acid Receptor GPR40 Protects from Bone Loss through Inhibition of Osteoclast Differentiation"

Copied!
2
0
0

Texte intégral

(1)

HAL Id: hal-02745557

https://hal.inrae.fr/hal-02745557

Submitted on 3 Jun 2020

HAL is a multi-disciplinary open access

archive for the deposit and dissemination of sci-entific research documents, whether they are pub-lished or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

The Free Fatty Acid Receptor GPR40 Protects from

Bone Loss through Inhibition of Osteoclast

Differentiation

Fabien Wauquier, Claire Philippe, Laurent Leotoing, Sylvie Mercier,

Marie-Jeanne Davicco, Patrice Lebecque, Jérome Guicheux, Paul Pilet,

Elisabeth Miot-Noirault, Vincent Poitout, et al.

To cite this version:

Fabien Wauquier, Claire Philippe, Laurent Leotoing, Sylvie Mercier, Marie-Jeanne Davicco, et al.. The Free Fatty Acid Receptor GPR40 Protects from Bone Loss through Inhibition of Osteoclast Differentiation. 2. International Congress of Translational Research in Human Nutrition ”Integrative Approaches in Nutrition Research”, Mar 2013, Clermond - Ferrand, France. 2013. �hal-02745557�

(2)

PO21

Title: THE FREE FATTY ACID RECEPTOR GPR40 PROTECTS FROM BONE LOSS THROUGH INHIBITION OF OSTEOCLAST DIFFERENTIATION

Authors and addresses: Fabien Wauquier1,2,3, Claire Philippe1,2,3, Laurent Léotoing1,2,3, Sylvie

Mercier1,2,3, Marie-Jeanne

Davicco1,2,3, Patrice Lebecque1,2,3, Jérôme Guicheux4,5 , Paul Pilet4,5 , Elisabeth Miot- Noirault2,6, Vincent Poitout7,8, Thierry Alquier7,8, Véronique Coxam1,2,3 and Yohann Wittrant1,2,3

1INRA, UMR 1019, UNH, CRNH Auvergne, F-63009 CLERMONT-FERRAND, FRANCE

2Clermont Université, Université d'Auvergne, Unité de Nutrition Humaine, BP 10448, F-63000 CLERMONT-FERRAND, FRANCE

3Equipe Alimentation, Squelette et Métabolismes

4Inserm, UMRS791, LIOAD, group STEP, F- 44042 NANTES, FRANCE

5PRES LUNAM, Université de Nantes, UFR Odontologie, 1 Place Alexis Ricordeau, F- 44042 NANTES, France

6Inserm, UMR 990, F-63000 CLERMONT-FERRAND

7Centre de Recherche du Diabète de Montréal ; Centre de Recherche du Centre Hospitalier de l’Université

de Montréal (CRCHUM)

8Département de Médecine, Université de Montréal, Montréal, Qc, Canada

Presenting author: Claire PHILIPPE

Abstract: The mechanisms linking fat intake to bone loss remain unclear. By demonstrating the

expression of the free fatty acid receptor Gcoupled Protein Receptor 40 (GPR40) in bone cells, we hypothesized that this receptor may

play a role in mediating the effects of fatty acids on bone remodeling. Using μCT analysis, we showed that GPR40-/- mice exhibit osteoporotic features suggesting a positive role of GPR40 on

bone density. In primary cultures of bone marrow, we showed that GW9508, a GRP40 agonist, abolished bone resorbing cell differentiation. This alteration of the Receptor Activator of NF-κB Ligand (RANKL)-induced osteoclast differentiation occurred via the

inhibition of the Nuclear Factor κB (NF-κB) signalling pathway as demonstrated by decrease in gene reporter activity, inhibitor of κB kinase (IKKα/β) activation, inhibitor of κB (IkBα) phosphorylation and Nuclear Factor of

Activated T cells 1 (NFATc1) expression. The GPR40-dependent effect of GW9508 was confirmed using shRNA interference in

osteoclast precursors and GPR40-/- primary cell cultures. In addition, in vivo administration of GW9508 counteracted ovariectomy-induced

bone loss in wild-type but not GPR40-/- mice enlightening the obligatory role of the GPR40 receptor. Then, in a context of growing prevalence of metabolic and age-related bone disorders, our results demonstrate for the first time in translational approaches that GPR40 is

a relevant target for the design of new

nutritional and therapeutic strategies to counter bone complications.

Click to buy NOW! PD F-XChange View er w w w .d ocu -tra ck.co

m Click to buy NOW!

PD F-XChange View er w w w .d ocu -tra ck.co m

Références

Documents relatifs

insulinotropic polypeptide (GIP) receptor deletion leads to reduced bone strength and

Taken together these findings show that TSG-6 ⫺/⫺ mice have increased bone mass compared with wild type littermates, which is contrary to what we had expected based on the effects

The simulations in this section demonstrate the effectiveness of the control system presented in this thesis for a spacecraft formation flying mission. Several aspects of.. a

Alignment of the chicken protein sequences of FFAR2 (supplementary data S7, Supplementary Material online) showed that the two arginine and two histidine, previously described

Lysophosphatidic Acid Receptor Type 1 (LPA 1 ) Plays a Functional Role in Osteoclast Differentiation and Bone Resorption Activity * □ S.. Received for publication, November 7, 2013,

At day 14, serum CTX and P1NP levels were elevated in both OVX groups compared with sham groups, indicative of increased bone turnover (Figure 8C); however, clopidogrel treat-

(A) Representative three- dimensional micro-CT reconstruction images and corresponding bar charts of femoral trabecular bone mass quantification with BV/TV of CTRL and

TAK-875 and FFAs Exhibit Distinct Signaling Signatures and Biased Agonism at GPR40 —Having established that TAK-875 is more efficacious than either PA or OA at promoting ␤-arres- tin